GLP-1 drugs and muscle: what does the science actually say?

Lean body mass (LBM) refers to everything in your body that isn't fat: muscle, bone, organs, water. When clinicians talk about losing lean mass during weight loss, they're most often concerned about muscle — its role in metabolism, physical function, and long-term health. For a broader view of what to monitor while on therapy, see our guide on GLP-1 side effects and what to track.

Any significant caloric deficit, including the appetite reduction that comes with GLP-1 therapy, can lead to some lean mass decline. "We're not used to having successful weight loss outcomes at the scale we've seen with GLP-1 analogs, other than with bariatric surgery. Having concerns about lean body mass is reasonable, but GLP-1s are one tool of many for weight loss," Dr. Armen Yerevanian, an endocrinologist at Massachusetts General Hospital, said in a Mass General Brigham Grand Rounds presentation on the topic.

The question isn't whether lean mass is affected. It's how much, and whether the muscle that remains is functionally preserved.

Langer et al., published in Cell Reports Medicine in 2026 (PMID 41850248), examined the effects of GLP-1 medicines on body composition in obese mice. The researchers found that GLP-1 medicines predominantly reduced body fat, alongside a small but statistically significant decrease in lean body mass.

This is preclinical data — findings from an animal model, not a human trial. They cannot be applied directly to human outcomes. What the study contributes is a mechanistic signal: at the cellular level in this model, GLP-1 medicines appear to preferentially target fat mass. Whether and to what degree this translates to human outcomes is an open question the study doesn't resolve.

The BELIEVE trial (NCT05616013), a phase 2 clinical trial published in Nature Medicine in March 2026, tested a specific strategy for protecting lean mass: combining semaglutide 2.4 mg with bimagrumab, an investigational antibody targeting type II activin receptors to promote muscle mass preservation.

At 72 weeks, the combination therapy resulted in preservation of lean mass while achieving greater fat mass reduction — including intra-abdominal fat — compared to semaglutide alone. Bimagrumab is investigational and not available by prescription.

What BELIEVE demonstrates is that it may be possible to decouple fat loss from lean mass loss with an add-on therapy. It does not resolve how much lean mass semaglutide alone causes to decline across diverse patient populations, and it does not yet confirm whether lean mass preservation translates to better functional outcomes over time.

• How much functional lean mass — muscle strength and quality, not just a number on a body composition scan — is affected by GLP-1 therapy in humans at scale, and over what timeframe

• Whether lean mass loss with GLP-1 therapy is meaningfully different from lean mass loss with equivalent weight reduction achieved by other means

• How lean mass outcomes differ across age groups, particularly in older adults and those with frailty

• Long-term metabolic consequences of GLP-1-related lean mass changes

"Just because a patient has measured decreases in lean body mass and fat-free mass doesn't necessarily mean that the functional status of the muscle is worse," noted Dr. Yerevanian. "This is an area of active investigation."

Mass General Brigham researchers, including Dr. Caroline Apovian of Brigham and Women's Hospital, reviewed available evidence and concluded that combining a high protein diet and consistent exercise with GLP-1 therapy offers the greatest measured benefit in preserving bone and muscle mass — compared to diet alone or exercise alone. This mirrors guidance we cover in GLP-1 maintenance after weight loss.

This recommendation is consistent with general guidance for preserving muscle during any weight-loss program. The right protein targets and exercise approach vary by individual. Your prescriber or a registered dietitian can help build a plan that fits your situation.

• Should we measure my body composition at baseline and track it during treatment?

• Given my age and starting fitness level, how much lean mass change is typical during treatment like this?

• What protein intake would you recommend at my current weight and activity level?

• Is resistance training appropriate for me to begin alongside GLP-1 therapy?

• At what point would lean mass changes prompt you to reconsider the treatment approach?

• Body weight, and body composition if your clinician recommends it (DEXA scan or a validated alternative)

• Physical function: are daily activities and effort level staying consistent?

• Dietary protein intake, especially as appetite decreases

• Resistance exercise adherence

Concern about lean mass loss during GLP-1 therapy deserves a serious answer. The evidence doesn't support dismissing it — but it also doesn't support alarm at the level you'll encounter in online forums. GLP-1 therapy appears to reduce fat mass preferentially, in both animal models and clinical trial settings, with some lean mass loss that appears consistent with other weight-loss approaches of similar magnitude.

The evidence-based approach to protecting muscle is the same as it has always been: adequate protein intake, consistent resistance exercise, and a monitoring plan if your clinician thinks it's appropriate.

Bring this conversation to your prescriber before or soon after starting treatment — not as a reason to avoid GLP-1 therapy, but as part of building a full treatment plan.